Soleno Therapeutics, Inc.

SAN FRANCISCO, May 5, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of the pending securities class action and the upcoming May 5, 2026 lead plaintiff deadline. The firm urges investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025 (the "Class Period"), and suffered significant losses to submit your losses now.

Case Name: City of Pontiac Police &Fire Ret. Sys. v. Soleno Therapeutics, Inc., et al.

Case No.: 26-cv-01979 (N.D. Cal.)

Contact: Reed Kathrein | 844-916-0895 | Submit SLNO Losses Here

The Allegations: Concealed Safety Risks and "Hocus-Pocus" Metrics:

The Soleno class action focuses on the company's repeated assurances regarding the safety, efficacy, and commercial launch of its flagship product, VYKAT™ XR (DCCR), for the treatment of Prader-Willi syndrome (PWS).

The complaint alleges that throughout the Class Period, Soleno misrepresented the commercial viability of DCCR by failing to disclose:

• Systemic Safety Omissions: The company allegedly downplayed significant evidence of safety concerns, including excess fluid retention and potential heart failure in children using the drug.
  
  
  
  
• Integrity Red Flags: A report by activist short seller Scorpion Capital highlighted that Soleno's Phase 3 clinical trials were purportedly reliant on a controversial physician in Gainesville, Florida, whose data exhibited irregularities consistent with data integrity failures.
  
  
  
  
• Inflated Launch Metrics: While Soleno claimed the DCCR launch "definitely exceeded our expectations," the complaint alleges that the "start forms" were artificially fueled by an "invisible hand" rather than genuine market demand.

The Alleged Corrective Disclosures and Stock Declines

On August 15, 2025, activist short seller Scorpion Capital published a report titled "Russian Roulette With Prader-Willi Children," detailing widespread adverse patient reactions and investigator skepticism. This report triggered an immediate double-digit decline in the stock price.

The truth allegedly fully materialized on November 4, 2025, when Soleno reported Q3 2025 financial results. Management admitted to a disruption in DCCR's launch trajectory, specifically acknowledging a lower number of patient start forms and increased discontinuations. On this news, SLNO stock plummeted 27% in a single day.

"Our investigation centers on the complaint's claims that Soleno allegedly bypassed critical safety protocols and used questionable metrics to maintain an inflated stock price," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the alleged claims.

Critical Deadline: May 5, 2026

If you purchased Soleno stock during the Class Period and suffered a significant loss, you have until May 5, 2026, to petition the Court to serve as lead plaintiff.

If you invested in Soleno and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now »

If you'd like more information and answers to frequently asked questions about the Soleno case and the firm's investigation, read more »

Whistleblowers: Persons with non-public information regarding Soleno should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email SLNO@hbsslaw.com.

About Hagens Berman

Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/slno-deadline-alert-hagens-berman-alerts-soleno-therapeutics-slno-investors-to-todays-lead-plaintiff-deadline-in-securities-class-action-302762934.html

SOURCE Hagens Berman Sobol Shapiro LLP

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, May 5, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO) and reminds investors of the May 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Soleno Phase 3 clinical trial program for DCCR had systematically downplayed, misrepresented, and/or concealed significant evidence of safety concerns potentially related to the administration of DCCR, including issues related to excess fluid retention in clinical trial participants; (2) as a result, the administration of DCCR to treat hyperphagia in individuals with PWS posed materially greater safety risks than disclosed by Soleno or its executives; and (3) consequently, DCCR had materially lower commercial viability and undisclosed risks related to the likelihood of significant and widespread adverse events after its commercial launch, including risks related to patient discontinuation rates, lower patient adoption, prescriber reluctance, adverse regulatory action, and potential reputational and legal fallout.

On August 15, 2025, Scorpion Capital LLC published a report critical of Soleno Therapeutics, Inc., its drug candidate DCCR, and the company's Phase 3 clinical trial program. The report alleged significant concerns regarding the drug's safety, efficacy, and clinical trial data. On this news, the price of Soleno common stock declined from a high of more than $77 per share on August 14, 2025 to close at approximately $68 per share on August 18, 2025, a decline of nearly 12% over two trading days.

Subsequently, on September 10, 2025, Soleno filed a Form 8-K with the U.S. Securities and Exchange Commission disclosing that a patient had died after taking DCCR.On this news, the price of Soleno common stock declined from more than $70 per share on September 9, 2025 to close at approximately $57 per share on September 11, 2025, a decline of approximately 19% over two trading days.

Lastly, on November 4, 2025, Soleno reported its financial results for the third quarter ended September 30, 2025, revealing that the earlier Scorpion Capital report had disrupted the launch trajectory of DCCR and raised concerns within the Prader-Willi syndrome community, resulting in fewer patient start forms and increased discontinuations. On this news, the price of Soleno common stock declined from nearly $64 per share on November 4, 2025 to close at approximately $47 per share on November 5, 2025, a one-day decline of approximately 27%.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. 

Faruqi & Faruqi, LLP also encourages anyone with information regarding Soleno's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Soleno Therapeutics class action, go to www.faruqilaw.com/SLNO or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

View original content to download multimedia:https://www.prnewswire.com/news-releases/slno-investor-notice-faruqi--faruqi-llp-reminds-soleno-therapeutics-slno-investors-of-securities-class-action-deadline-on-may-5-2026-302762329.html

SOURCE Faruqi & Faruqi, LLP